The Zhitong Finance App learned that Tiger Pharmaceuticals (03347) rose more than 4% in the intraday period. As of press release, it had risen 3.63% to HK$47, with a turnover of HK$197,94 million.

According to the news, according to Tiger Pharmaceuticals official WeChat, Tiger Pharmaceuticals and Dean Diagnostics recently signed a strategic cooperation agreement in Hangzhou. The two sides will carry out in-depth cooperation in the fields of AI pharmaceutics, clinical trials, and accompanying diagnosis, and jointly establish a leading domestic “innovative drug development-accompanying diagnosis” integrated collaborative system, so that diagnosis and data capabilities can be integrated into the drug development process earlier.

In the commercialization stage, Dean Diagnostics will rely on a nationwide ICL (Independent Medical Laboratory) network to provide a rapid commercial implementation channel for accompanying diagnosis after approval of new drugs; the two sides will also jointly carry out real-world research on accompanying diagnostic products after marketing to accumulate high-quality clinical evidence for the expansion of indications, inclusion of clinical guidelines, and fee entry for testing programs, and improve the closed loop of commercialization evidence.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.